IS8. The Ongoing Debate Surrounding Atypicals: Are the Benefits Worth
the Risks?Supported by Solvay Pharmaceuticals and Wyeth
IS9. Still Sleepy After All These Cures: Hypersomnia in PsychiatrySupported by Cephalon Inc.
IS10. Deconstructing Attention and Cognition in ADHD: New Understandings
for Improved ManagementSupported by McNeil Pediatrics
IS11. Long-Term Treatment Approaches for Schizophrenia: Comparing
Maintenance and Recovery ModelsSupported by Bristol-Myers Squibb
IS12. Dark Horizons: Depression and Cognitive ImpairmentSupported by Forest Laboratories Inc.
IS13. Planning for Success in Schizophrenia ManagementSupported
by Janssen Pharmaceutica and Research Foundation
IS14. Making Every Sheep Count: Evidence-Based Approaches to Treating
InsomniaSupported by Takeda Pharmaceuticals North America
IS15. Rethinking Bipolar Disorder: Implications of ComorbiditiesSupported by AstraZeneca Pharmaceuticals
IS16. Caring for Our Most Challenging Patients With Depression: An
Interactive Forum on Novel TreatmentsSupported by Cyberonics
L1.Carl P. Malmquist, M.D., AAPL/APA's Manfred S. Guttmacher
IS17. How Comorbid Is ADHD? Results From Epidemiological and Clinical
StudiesSupported by Shire U.S. Inc.
IS18. The Alcohol-Dependent Patient: Improving Outcomes Through
AdherenceSupported by Cephalon Inc.
IS19. Weighing the Risks and Benefits of Atypical Antipsychotics: Can We
Have Our Cake and Eat It Too?Supported by Bristol-Myers Squibb
IS20. STAR*D Findings: Implications for Patients, Clinicians,
and Other StakeholdersSupported by Forest Laboratories Inc.